dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorInstituto de Ciências Biomédicas Abel Salazar - Universidade do Porto (ICBAS-UP)
dc.date.accessioned2020-12-12T02:49:26Z
dc.date.accessioned2022-12-19T21:24:13Z
dc.date.available2020-12-12T02:49:26Z
dc.date.available2022-12-19T21:24:13Z
dc.date.created2020-12-12T02:49:26Z
dc.date.issued2020-12-01
dc.identifierBiochemical Pharmacology, v. 182.
dc.identifier1873-2968
dc.identifier0006-2952
dc.identifierhttp://hdl.handle.net/11449/202084
dc.identifier10.1016/j.bcp.2020.114214
dc.identifier2-s2.0-85090592824
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5382718
dc.description.abstractObesity is a worldwide health problem which have reached pandemic proportions, now also including low and middle-income countries. Excessive or abnormal fat deposition in the abdomen especially in the visceral compartment is tightly associated with a high metabolic risk for arterial hypertension, type II diabetes, cardiovascular diseases, musculoskeletal disorders (especially articular degeneration) and some cancers. Contrariwise, accumulation of fat in the subcutaneous compartment has been associated with a neutral metabolic impact, favoring a lower risk of insulin resistance. Obesity results more often from an avoidable imbalance between food consumption and energy expenditure. There are several recommended strategies for dealing with obesity, including pharmacological therapies, but their success remains incomplete and may not compensate the associated adverse effects. Purinergic signaling operated by ATP and its metabolite, adenosine, has attracted increasing attention in obesity. The extracellular levels of purines often reflect the energy status of a given cell population. Adenine nucleotides and nucleosides fine tuning control adipogenesis and mature adipocytes function via the activation of P2 and P1 purinoceptors, respectively. These features make the purinergic signaling cascade a putative target for therapeutic intervention in obesity and related metabolic syndromes. There are, however, gaps in our knowledge regarding the role of purines in adipocyte precursors differentiation and mature adipocytes functions, as well as their impact among distinct adipose tissue deposits (e.g. white vs. brown, visceral vs. subcutaneous), which warrants further investigations before translation to clinical trials can be made.
dc.languageeng
dc.relationBiochemical Pharmacology
dc.sourceScopus
dc.subjectAdipogenesis
dc.subjectAdipose tissue
dc.subjectEctonucleotidases
dc.subjectObesity
dc.subjectPurinergic signaling
dc.subjectPurinoceptors
dc.titlePitfalls and challenges of the purinergic signaling cascade in obesity
dc.typeOtros


Este ítem pertenece a la siguiente institución